Nasdaq

Nevro Announces U.S. Launch of Senza® Omnia(TM) Spinal Cord Stimulation System to Treat Chronic Pain

REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today ...
Nasdaq

Nevro Announces CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
EDN

Nevro Corp. Announces Publication of Positive Six-Month Clinical Data for Senza® HF10™ High-Frequency Spinal Cord Stimulation Therapy in Europe

The findings were published in Neuromodulation: Technology at the Neural Interface, a peer-reviewed publication of the International Neuromodulation Society. The 83-patient study evaluated patients ...
BioWorld

Nevro takes a step closer to gaining FDA nod for HF10 therapy in PDN

Nevro Corp. has submitted a premarket approval supplement to the U.S. FDA seeking a green light for its Senza system to treat chronic pain associated with painful diabetic neuropathy (PDN). This ...